Robert Winkler

2.4k total citations · 1 hit paper
59 papers, 1.3k citations indexed

About

Robert Winkler is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Robert Winkler has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 20 papers in Epidemiology and 16 papers in Molecular Biology. Recurrent topics in Robert Winkler's work include Neuroendocrine Tumor Research Advances (14 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Robert Winkler is often cited by papers focused on Neuroendocrine Tumor Research Advances (14 papers), Lung Cancer Research Studies (14 papers) and Colorectal Cancer Treatments and Studies (11 papers). Robert Winkler collaborates with scholars based in United States, Spain and France. Robert Winkler's co-authors include Eric Van Cutsem, James C. Yao, Edward M. Wolin, Marc Peeters, Valentine Jehl, Marianne Pavel, Éric Baudin, David Lebwohl, Judith Klimovsky and Kjell Öberg and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Robert Winkler

56 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

2011 767 citations Marianne Pavel, Marc Peeters et al. profile →

Peers

Countries citing papers authored by Robert Winkler

Since Specialization

Citations

This map shows the geographic impact of Robert Winkler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Winkler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Winkler more than expected).

Fields of papers citing papers by Robert Winkler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Winkler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Winkler. The network helps show where Robert Winkler may publish in the future.

Co-authorship network of co-authors of Robert Winkler

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Winkler. A scholar is included among the top collaborators of Robert Winkler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Winkler. Robert Winkler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Alexander T. Pearson, (unknown), Kedar Kirtane, Emily L. Bellile, Krithika Suresh, (unknown), Francis P. Worden, Christine H. Chung, Everett E. Vokes, J. Chad Brenner, Jonathan B. McHugh, Yifan Zhai, Tommy Fu, Robert Winkler, Paul Swiecicki	2
2	Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents 2024 ·Targeted Oncology ·Neeta Somaiah, Bishnuhari Paudyal, Robert Winkler, Brian A. Van Tine, Angela C. Hirbe	4
3	Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment 2019 ·British Journal of Clinical Pharmacology ·Muhammad Wasif Saif, Lee S. Rosen, Michelle A. Rudek, Weijing Sun, Dale R. Shepard, Carlos Becerra, (unknown), (unknown), Robert Winkler	7
4	Phase I dose-escalation study of TAS-120, a highly selective, covalently bound FGFR inhibitor, in patients with advanced solid tumors 2018 ·Clinical Trials ·Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, Ben Tran, Helen He, Robert Winkler, Cinta Hierro, Hendrik‐Tobias Arkenau	1
5	Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi’s 2018 ·Annals of Oncology ·Ben Tran, Funda Meric‐Bernstam, Hendrik‐Tobias Arkenau, Rastislav Bahleda, Robin Kate Kelley, Cinta Hierro, Daniel H. Ahn, Andrew X. Zhu, Milind Javle, Robert Winkler, Huan He, Jee‐Fu Huang, Lipika Goyal	15
6	Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Robert J. Mayer, Howard S. Höchster, Steven J. Cohen, Robert Winkler, Lukas Makris, Axel Grothey	21
7	Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma 2017 ·Annals of Oncology ·Lipika Goyal, Hendrik-Tobias Arkenau, Ben Tran, Jean‐Charles Soria, Rastilav Bahleda, Gabriel Mak, Andrew X. Zhu, Milind Javle, Hiroshi Hirai, Fabio Benedetti, (unknown), Robert Winkler, Funda Meric‐Bernstam	18
8	The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer 2017 ·European Journal of Cancer ·Eric Van Cutsem, R. Mayer, Stéphanie Laurent, Robert Winkler, (unknown), Manuel Benavides, (unknown), Fabienne Portales, Fortunato Ciardiello, Salvatore Siena, Kensei Yamaguchi, Kei Muro, Tadamichi Denda, Yasushi Tsuji, Lukas Makris, Patrick J. Loehrer, Heinz‐Josef Lenz, Atsushi Ohtsu	62
9	PD-025 RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment 2016 ·Annals of Oncology ·Josep Tabernero, (unknown), Atsushi Ohtsu, Takayuki Yoshino, Rocio García‐Carbonero, Alessandro Pastorino, Marc Peeters, Robert Winkler, Lukas Makris, Mona Wahba, Alberto Zaniboni, Yoshifumi Shimada, Kentaro Yamazaki, Yoshito Komatsu, Howard S. Höchster, Heinz‐Josef Lenz, Alfredo Falcone, Bach Xuan Tran, Eric Van Cutsem	3
10	Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. 2016 ·Journal of Clinical Oncology ·Robert J. Mayer, Atsushi Ohtsu, Takayuki Yoshino, Alfredo Falcone, Rocio García‐Carbonero, Guillem Argilés, (unknown), Marc Peeters, Lukas Makris, Alberto Zaniboni, Yasuhiro Shimada, Kentaro Yamazaki, Yoshito Komatsu, Howard S. Höchster, Heinz‐Josef Lenz, Ben Tran, Robert Winkler, (unknown), Mona Wahba, Eric Van Cutsem, (unknown)	4
11	Analysis of Progression-Free Survival (PFS) by Prior Chemotherapy Use and Updated Safety in RADIANT-3: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial of Everolimus in Patients with Advanced Low- or Intermediate-Grade Pancreatic Neuroendocrine Tumors (pNET) 2012 ·Pancreas ·Timothy J. Hobday, Rodney F. Pommier, Eric Van Cutsem, Ashok Panneerselvam, Stephen Saletan, Robert Winkler, James C. Yao	2
12	Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3) 2011 ·Pancreas ·Manisha H. Shah, Kjell Öberg, Tetsuhide Ito, Catherine Lombard‐Bohas, Edward M. Wolin, Eric Van Cutsem, Carolin Sachs, Robert Winkler, Jeremie Lincy, (unknown), James C. Yao	1
13	Prognostic Value of Chromogranin A and Neuron-Specific Enolase in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Study Results: 2011 ACG Presidential Poster 2011 ·The American Journal of Gastroenterology ·Jonathan Strosberg, Lowell Anthony, Lucas Sidéris, Jérémie Lebrec, Zenta Tsuchihashi, Robert Winkler, James C. Yao	1
14	6573 POSTER Effect of Everolimus Treatment on Markers of Angiogenesis in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET) – Results From the Phase III RADIANT-3 Study 2011 ·European Journal of Cancer ·James C. Yao, Zenta Tsuchihashi, A. Panneerselvam, Robert Winkler, Roberto Bugarini, (unknown)	7
15	Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. 2011 ·Journal of Clinical Oncology ·James C. Yao, Stefano Ricci, Robert Winkler, Valentine Jehl, Marianne Pavel	5
16	Impact of Treatment with Infliximab on Serum Cytokine Profile of Patients with Rheumatoid and Psoriatic Arthritis 2007 ·Annals of the New York Academy of Sciences ·Howard Amital, Vivian Barak, Robert Winkler, Alan Rubinow	15
17	Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme 2007 ·The Cancer Journal ·Tamar Fisher, (unknown), Gad Lavie, Jasmine Jacob‐Hirsch, (unknown), Sharon Zeligson, Robert Winkler, Anthony Simon, Ninette Amariglio, Gideon Rechavi, Amos Toren	29
18	Low viscosity histidine-tryptophan-ketoglutarate graft flush improves subsequent extended cold storage in University of Wisconsin solution in an extracorporeal rat liver perfusion and rat liver transplantation model 2006 ·Liver Transplantation ·Gero Puhl, P. Olschewski, Wenzel Schöning, (unknown), (unknown), Robert Winkler, Ulf P. Neumann, Thomas Schubert, Volker Schmitz, P. Neuhaus	24
19	Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications 2006 ·Journal of Viral Hepatitis ·Pierre Pradat, Hans L. Tillmann, Sílvia Sauleda, Jean Henrik Braconier, Giorgio Maria Saracco, Mark Thursz, Robert Goldin, Robert Winkler, A. Albertí, (unknown), Stephanos J. Hadziyannis, M. Rizzetto, Howard Thomas, Michael P. Manns, C. Trépo, (unknown)	45
20	Tumor necrosis factor-? blocking agent as a treatment for nephrotic syndrome 2004 ·Pediatric Nephrology ·David Raveh, Ovadia Shemesh, (unknown), Robert Winkler, Vivian Barak	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact